| Challenges and strategies in anti-cancer nanomedicine development: An industry perspective JI Hare, T Lammers, MB Ashford, S Puri, G Storm, ST Barry Advanced drug delivery reviews 108, 25-38, 2017 | 1072 | 2017 |
| Insights into low molecular mass organic gelators: a focus on drug delivery and tissue engineering applications KJ Skilling, F Citossi, TD Bradshaw, M Ashford, B Kellam, M Marlow Soft matter 10 (2), 237-256, 2014 | 395 | 2014 |
| An evaluation of pectin as a carrier for drug targeting to the colon M Ashford, J Fell, D Attwood, H Sharma, P Woodhead Journal of Controlled Release 26 (3), 213-220, 1993 | 359 | 1993 |
| Studies on pectin formulations for colonic drug delivery M Ashford, J Fell, D Attwood, H Sharma, P Woodhead Journal of Controlled Release 30 (3), 225-232, 1994 | 304 | 1994 |
| An in vivo investigation into the suitability of pH dependent polymers for colonic targeting M Ashford, JT Fell, D Attwood, H Sharma, PJ Woodhead International journal of pharmaceutics 95 (1-3), 193-199, 1993 | 276 | 1993 |
| Targeting drugs to the colon: delivery systems for oral administration M Ashford, J Fell Journal of drug targeting 2 (3), 241-257, 1994 | 249 | 1994 |
| Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres DP Ivanov, TL Parker, DA Walker, C Alexander, MB Ashford, PR Gellert, ... PloS one 9 (8), e103817, 2014 | 243 | 2014 |
| Cancer nanomedicine: is targeting our target? T Lammers, F Kiessling, M Ashford, W Hennink, D Crommelin, G Storm Nature Reviews Materials 1 (9), 1-2, 2016 | 231 | 2016 |
| Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo S Ashton, YH Song, J Nolan, E Cadogan, J Murray, R Odedra, J Foster, ... Science translational medicine 8 (325), 325ra17-325ra17, 2016 | 215 | 2016 |
| An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting M Ashford, JT Fell, D Attwood, PJ Woodhead International journal of pharmaceutics 91 (2-3), 241-245, 1993 | 212 | 1993 |
| Penetration and uptake of nanoparticles in 3D tumor spheroids A Tchoryk, V Taresco, RH Argent, M Ashford, PR Gellert, S Stolnik, ... Bioconjugate chemistry 30 (5), 1371-1384, 2019 | 171 | 2019 |
| Chitosan/hyaluronic acid nanoparticles: rational design revisited for RNA delivery E Lallana, JM Rios de la Rosa, A Tirella, M Pelliccia, A Gennari, ... Molecular pharmaceutics 14 (7), 2422-2436, 2017 | 138 | 2017 |
| Evaluating the efficiency of hyaluronic acid for tumor targeting via CD44 A Spadea, JM Rios de la Rosa, A Tirella, MB Ashford, KJ Williams, ... Molecular pharmaceutics 16 (6), 2481-2493, 2019 | 91 | 2019 |
| Local delivery of macromolecules to treat diseases associated with the colon A Bak, M Ashford, DJ Brayden Advanced drug delivery reviews 136, 2-27, 2018 | 90 | 2018 |
| The effects of Pluronic® block copolymers and Cremophor® EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells F Seeballuck, MB Ashford, CM O'Driscoll Pharmaceutical research 20, 1085-1092, 2003 | 88 | 2003 |
| The emulsification and solubilisation properties of polyglycolysed oils in self‐emulsifying formulations M Devani, M Ashford, DQM Craig Journal of pharmacy and pharmacology 56 (3), 307-316, 2004 | 87 | 2004 |
| Stimulation of Triglyceride-Rich Lipoprotein Secretion by Polysorbate 80: In Vitro and in Vivo Correlation Using Caco-2 Cells and a Cannulated Rat Intestinal … F Seeballuck, E Lawless, MB Ashford, CM O’Driscoll Pharmaceutical research 21, 2320-2326, 2004 | 81 | 2004 |
| A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system YH Song, E Shin, H Wang, J Nolan, S Low, D Parsons, S Zale, S Ashton, ... Journal of Controlled Release 229, 106-119, 2016 | 74 | 2016 |
| Bioavailability–physicochemical and dosage form factors M Ashford Aulton’s pharmaceutics: the design and manufacture of medicines. Amsterdam …, 2013 | 74 | 2013 |
| Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy CM Patterson, SB Balachander, I Grant, P Pop-Damkov, B Kelly, ... Communications Biology 4 (1), 112, 2021 | 71 | 2021 |
